BeiGene Corporate Overview

Beigene is a global oncology company that was built differently to deliver innovative medicines faster, more equitably and affordably around the world.


Our founding belief is that there is a better way to bring innovative treatments to patients around the world. We are an oncology powerhouse with a deep, diverse pipeline fueled by one of the industry's largest and most productive research teams. Our two foundational medicines, BTK inhibitor BRUKINSA® (zanubrutinib) and PD-1 inhibitor TEVIMBRA® (tislelizumab), demonstrate the strength of our science and our mission to improve treatment outcomes for patients.

Today, **more than 10,000** colleagues operate in more than **40 markets** across **five continents**. **More than 1 million** patients have been treated with our medicines, reflecting our expansive global reach and deep commitment to access.



Innovative Science Responding to the Greatest Areas of Need

We have one of the largest and most productive oncology research teams in the world, with more than 1,100 highly-credentialed scientists with a proven track record of developing innovative medicines that address significant unmet needs. We also have one of the largest and most compelling oncology pipelines in the industry covering 80% of the world's cancers by incidence.



Global Capabilities to Reach More Patients

in

We are challenging industry conventions with our own in-house drug discovery and development capabilities. In just over a decade, this model has generated one of the industry's most robust oncology pipelines, conducted more than 130 clinical trials among more than 20,000 patients, and received regulatory approvals in more than 70 markets across three internally developed medicines.

Our fully integrated manufacturing capabilities also allow us to speed-up our clinical development efforts while ensuring the highestquality production of our clinical and commercial portfolio of small-molecule, biologics and emerging modality therapeutics.



Our Princeton West Innovation Campus in New Jersey houses a state-of-the art, clinical and commercial-stage biologics manufacturing facility and clinical R&D center, which complement our existing capabilities around the world.

For more information visit:









